Revenue, 2025

USD 4.09 Billion

Forecast, 2035

USD 20 Billion

CAGR, 2026-2035

17.2%

Report Coverage

United States

U.S. Cell and Gene Therapy Market Trends for 2026

The U.S. cell and gene therapy market size was estimated at USD 4.09 billion in 2025 and is predicted to increase from USD 4.74 billion in 2026 to approximately USD 20 billion by 2035, expanding at a CAGR of 17.2% from 2026 to 2035. The market is rapidly expanding due to strong clinical innovation, increasing approvals of advanced therapies, and growing demand for curative treatments in oncology and rare genetic disorders. It is driven by heavy biotech investment, breakthroughs in gene editing and personalized medicine, and is positioned as a global leader in next-generation therapeutic development.

Key Takeaways

• U.S. cell and gene therapy sector pushed the market to USD 4.74 billion by 2026.
• Long-term projections show USD 20 billion valuation by 2035.
• Growth is expected at a steady CAGR of 17.2% in between 2026 to 2035.
• Cell and gene therapy market is set to grow from US$ 8.94 billion in 2025 to US$ 47.18 billion by 2035 at 18.1% CAGR.
• By therapy type, the cell therapy segment dominated the market with shares of 66.20% in 2025.
• By therapy type, the gene therapy segment held the second-largest share of 33.80% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By indication/therapeutic area, the oncology segment held a dominant share of 39.50% in 2025.
• By indication/therapeutic area, the genetic disorders segment held 12.10% share in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By vector type, the viral vectors segment held a dominant share of 72% in 2025.
• By vector type, the non-viral vectors segment held the second-largest share of 28% in 2025 and is expected to grow at the fastest CAGR in the U.S. cell and gene therapy market during the forecast period.
• By manufacturing type, the in-house segment held a dominant share of 46.70% in 2025.
• By manufacturing type, the contract development & manufacturing (CDMO) segment held the second-largest share of 37.50% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By end user, the hospitals and specialty clinics segment led the market with a share of 64.50% in 2025.
• By end user, the cancer treatment centers segment held the second-largest share of 22.70% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period.

Innovation Surge Driving U.S. Cell & Gene Therapy Growth

The U.S. cell and gene therapy market focuses on developing advanced treatments that modify or replace cells and genes to treat or cure diseases at their root cause. It is a rapidly growing sector driven by innovation in personalized medicines, especially for cancer and rare genetic disorders. The U.S. cell and gene therapy market is growing rapidly due to increasing approvals of advanced therapies, a strong pipeline of clinical trials, and rising demand for curative treatments in cancer and rare diseases. Significant investments from biotech and pharmaceutical companies, along with breakthroughs in gene editing and personalized medicine, further accelerate innovation, while supportive regulatory frameworks and advanced healthcare infrastructure strengthen market expansion.

Curative Impact of Oncology Treatments in the U.S.

How Can AI Affect the U.S. Cell & Gene Therapy Market?

AI is transforming the market by accelerating drug discovery, optimizing clinical trial design, and improving patient selection through predictive analytics. It enhances manufacturing efficiency and quality control, reducing costs and timelines. AI-driven insights also support personalized treatment development, increasing success rates and enabling faster commercialization of advanced therapies.

Trend and Future Outlook of the U.S. Cell & Gene Therapy Market?

Shift Toward Personalized & Precision Therapies

The market is increasingly focused on patient-specific treatments, including autologous cell therapies and targeted gene editing. Advances in precision medicine are improving treatment efficacy, especially in oncology and rare genetic disorders, driving demand for customized therapeutic solutions.

Expansion of Manufacturing & Commercial Scale-Up

Companies are investing in automated, scalable manufacturing technologies to meet rising demand and reduce costs. Innovations in vector production, cell processing, and supply chain optimization are improving accessibility and supporting the transition from clinical trials to large-scale commercialization.

Integration of Advanced Technologies like AI & Gene Editing

The adoption of AI, CRISPR, and next-generation platforms is accelerating research and development. These technologies enhance target identification, streamline trials, and improve success rates, positioning the U.S. as a leader in next-generation therapeutic innovation and future market growth.

 Key Indicators and Highlights

Segmental Insights

By Therapy Type Insights

The Cell Therapy Segment Dominated the Market in 2025

The cell therapy segment dominated the U.S. cell and gene therapy market with shares of 66.20% in 2025 due to the higher number of approved therapies. particularly in oncology, and the strong clinical success of treatments like CAR-T. Increased adoption in hospitals, growing investment in regenerative medicines, and faster commercialization compared to gene therapies further supported its leadership, while expanding applications across multiple disease areas strengthened its market share.

The gene therapy segment held the second-largest share of 33.80% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to growing approvals of innovative, one-time treatments targeting rare genetic disorders and chronic conditions. Strong clinical pipelines, increasing investment in gene-editing technologies, and rising awareness of long-term therapeutic benefits supported its expansion. Additionally, improving regulatory support and advancements in viral vector delivery systems further strengthened its adoption across specialized treatment areas.

By Indication/Therapeutic Area Insights

The Oncology Segment Led the Market in 2025 with the Largest Share

The oncology segment held a dominant share in the U.S. cell and gene therapy market of 39.50% in 2025 due to the high prevalence of cancer and strong demand for advanced, targeted treatments. Significant success of cell therapies like CAR-T, extensive clinical pipelines, and continuous approvals accelerated adoption. Additionally, substantial investments from biotech and pharmaceutical companies, along with favorable reimbursement and regulatory support, further strengthened oncology’s dominant position in the market.

The musculoskeletal/orthopedic disorders segment held the second-largest share of 21.30% in 2025 due to the high prevalence of conditions like osteoarthritis, osteoporosis, and sports injuries. Growing demand for regenerative therapies, including stem cell-based treatments, is driving adoption. Increased aging populations, rising orthopedic procedures, and continuous research in tissue engineering repair further support the strong growth and expansion of this segment.

The genetic disorders segment held 12.10% share in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to increasing focus on curative gene therapies targeting rare and inherited diseases. Advancements in gene editing technologies, expanding clinical pipelines, and rising regulatory approvals are accelerating development. Additionally, growing investments, improved diagnostic capabilities, and strong demand for long-term treatment solutions are driving rapid adoption in this segment.

The infectious disease segment held 5.40% of the U.S. cell and gene therapy market share in 2025 due to increasing focus on advanced therapies for viral infections, including HIV and emerging pathogens. Rising demand for long-lasting and potentially curative treatment, along with expanding research in gene-modified immune cells and antiviral gene therapies, is driving growth. Additionally, heightened awareness after global outbreaks and increased funding for infectious disease innovation are accelerating development and adoption in this segment.

By Vector Type Insights

The Viral Vectors Segment Led the Market in 2025 with the Largest Share

The viral vectors segment held a dominant share of 72% in the U.S. cell and gene therapy market in 2025 due to their high efficiency in delivering genetic material into target cells and proven success in approved gene therapies. Strong clinical validation, especially with adeno-associated and lentiviral vectors, supported widespread adoption. Additionally, well-established manufacturing processes, regulatory familiarity, and their ability to enable long-term gene expression made viral vectors the preferred choice over non-viral alternatives.

The non-viral vectors segment held the second-largest share of 28% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to its advantages in safety, lower immunogenicity, and reduced risk of insertional mafugenesis compared to the viral system. Growing research in liquid nanoparticles and polymer-based delivery, along with easier manufacturing and scalability, supported adoption. Additionally, increasing use in mRNA therapies and gene editing applications further strengthened its position in the market.

By Manufacturing Type Insights

The In-house Segment held a Dominant Position in the Market in 2025

The in-house segment held a dominant share of 46.70% in the U.S. cell and gene therapy market in 2025 due to the need for strict quality control, intellectual property protection, and process standardization in complex cell and gene therapy manufacturing. Companies prefer internal production to ensure consistency, reduce dependency on third parties, and accelerate timelines. Additionally, large investments in dedicated manufacturing infrastructure and capacity expansion further strengthened its dominance in in-house operations.

The contract development & manufacturing (CDMO) segment held the second-largest share of 37.50% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to rising outsourcing by biotech firms lacking in-house capabilities. CDMOs offer specialized expertise, flexible capacity, and cost-effective production for complex therapies. Increasing clinical trials activity, scalability needs, and faster time-to-market further drove demand, while partnership between pharma companies and CDMOs strengthened their role in the cell and gene therapy value chain.

The hybrid models segment held 16% of the U.S. cell and gene therapy market share in 2025 as companies seek a balance between in-house control and outsourced flexibility. It allows firms to maintain critical processes internally while leveraging CDMOs for scalability and cost efficiency. This approach supports risk mitigation, faster commercialization, and optimized capacity utilization. Additionally, the increasing complexity of cell and gene therapies is driving the adoption of hybrid strategies to enhance operational efficiency and supply chain resilience.

By End Use Insights

The Hospitals and Specialty Clinics Segment Dominated the Market in 2025

The hospitals and specialty clinics segment led the U.S. cell and gene therapy market with a share of 64.50% in 2025 due to their advanced infrastructure and ability to handle complex cell and gene therapies requiring specialized administration and monitoring. These facilities have skilled professionals, access to critical care, and established treatment protocols. Additionally, higher patient inflow, availability of reimbursement support, and integration with clinical trials further strengthen their leading role in therapy delivery and adoption.

The cancer treatment centers segment held the second-largest share of 22.70% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to the high concentration of oncology patients and increasing adoption of advanced therapies like CAR-T. These centers offer specialized expertise, dedicated infrastructure, and access to clinical trials. Additionally, rising cancer incidence, growing focus on personalized treatment, and collaborations with biotech firms are driving greater utilization of cell and gene therapies in these settings.

The research institutes segment held 12.80% of the U.S. cell and gene therapy market share in 2025 due to increasing focus on early-stage discovery and translational research in cell and gene therapies. Rising funding from government and private organizations, along with growing academic industry collaboration. is accelerating innovation. These institutes play a key role in clinical trials development, biomarker discovery, and technology, driving pipeline growth and supporting long-term market expansion.

Global Cell and Gene Therapy Market Growth

The cell and gene therapy market size touched US$ 8.94 billion in 2025, with expectations of climbing to US$ 10.44 billion in 2026 and hitting US$ 47.18 billion by 2035, driven by a CAGR of 18.1% over the forecast period.

Supply Chain Analysis

Clinical Trials

• The U.S. cell and gene therapy landscape is progressing quickly, with strong clinical focus on CAR-T treatments for cancer and viral vector-based therapies for rare genetic conditions. More than 2,600 investigational therapies are currently being regulated by the FDA’s Office of Therapeutic Products, with many targeting blood disorders and inherited diseases.
• Key players: Novartis AG, Gilead Sciences, Bristol Myers Squibb, and Bluebird Bio.

Regulatory Approvals

• In the U.S., cell and gene therapy approvals are regulated by the Center for Biologics Evaluation and Research under the U.S. Food and Drug Administration. Developers must submit a Biologics License Application to demonstrate safety, quality, and effectiveness before commercialization under the Public Health Service Act.
• Key players: Novartis AG, Gilead Sciences, Bristol Myers Squibb, and Pfizer Inc.

Patient Support and Services

• In the U.S., cell and gene therapy approvals are overseen by the Center for Biologics Evaluation and Research under the U.S. Food and Drug Administration, where companies must submit a Biologics License Application to prove safety, quality, and efficacy.
• Key players: Novartis AG, Gilead Sciences, Bristol Myers Squibb, and Pfizer Inc.

Top Vendors in the U.S. Cell and Gene Therapy Market & Their Offerings

SWOT Analysis

Strengths

• Strong innovation ecosystem supported by leading biotech firms and research institutions.
• Robust regulatory framework led by the U.S. Food and Drug Administration, ensuring high-quality standards.
• High number of clinical trials and approved advanced therapies.
• Significant investment and funding from both public and private sectors.

Weaknesses

• High treatment and development costs limit widespread accessibility.
• Complex manufacturing and supply chain requirements.
• Reimbursement challenges for expensive one-time therapies.
• Limited long-term safety and efficacy data for newer therapies.

Opportunities

• Expansion into rare and genetic disease treatments with curative potential.
• Advancements in gene editing technologies like CRISPR.
• Growing adoption of personalized medicine approaches.
• Increasing partnerships between biotech companies and research institutes.

Threats

• Stringent regulatory hurdles and evolving compliance requirements.
• Ethical concerns related to gene editing and genetic modification.
• Competition from alternative therapies and emerging technologies.
• Pricing pressures and policy changes impacting market growth.

What are the Recent Developments in the U.S. Cell and Gene Therapy Market?

• In April 2026, the U.S. Food and Drug Administration approved Otarmeni (lunsotogene parvec-cwha), marking the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. This treatment is indicated for pediatric and adult patients with severe-to-profound sensorineural hearing loss associated with biallelic OTOF gene variants.
• In March 2026, Children’s Hospital Los Angeles is committed to providing top-tier access to cutting-edge cell and gene treatments for children facing serious or life-threatening illnesses. The facility recently grew its portfolio to 12 FDA-cleared therapies, making it the leading pediatric center on the West Coast for these advanced medical options.

Segments Covered in the Report

By Therapy Type

• Cell Therapy
• Gene Therapy

By Indication/Therapeutic Area

• Oncology
• Genetic Disorders
• Neurology Disorders
• Cardiovascular Diseases
• Ophthalmology
• Musculoskeletal/Orthopedic Disorder
• Infectious Diseases
• Metabolic Disorders
• Others

By Vectors Type

• Viral Vectors
• Non-viral Vectors

By Manufacturing Type

• In-house (Biotech/Pharma-Owned Facilities)
• Contract Development & Manufacturing (CDMO)
• Hybrid Models

By End Use

• Hospitals and Specialty Clinics
• Cancer Treatment Centers
• Research Institutes